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Background: Anaemia in pregnancy is a major public health problem especially in the low-income countries where
it is highly prevalent. There has been no recent study in Uganda about the factors associated with anaemia in
pregnancy. We aimed to assess the current haemoglobin (Hb) status and factors associated with anaemia
(Hb < 11.0 g/dl) in pregnant women in Mpigi, Uganda.
Methods: We assessed Hb levels of 2436 pregnant women at 28+ weeks of gestation at six health facilities, who were
approached to participate in a stepped-wedge cluster-randomised trial of antenatal distribution of misoprostol
(for self-administration after home birth or when oxytocin is not available). Women were administered a questionnaire
and their baseline blood haemoglobin was examined using portable HemoCueR Hb 301 system. Predictors of anaemia
were estimated using linear and logistic regression analysis.
Results: The mean Hb was 11.5 (±1.38) g/dl and prevalence of anaemia (Hb < 11.0 g/dl) was 32.5% (95% CI 30.6%,
34.3%). After adjusting for measured confounders, factors associated with increased risk of anaemia in pregnancy
were malaria infection (OR: 1.32, 95% CI: 1.11, 1.58), Human Immuno-deficiency Virus infection (OR: 2.13, 95% CI:
1.36, 2.90) and lack of iron supplementation (OR: 1.66, 95% CI: 1.36, 2.03). Intermittent presumptive treatment of
malaria, maternal age and parity showed a weak association with anaemia in pregnancy
Conclusion: The high prevalence of anaemia in pregnancy in our setting highlights the need to put more effort
in the fight against malaria and HIV, and also ensure that pregnant women access iron supplements early in
pregnancy.
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Globally, anaemia in pregnancy is a public health problem
[1]. It is estimated that more than half of the pregnant
women in the world are anaemic, with resource-limited
settings having a higher burden than high-income nations
[1]. Anaemia in pregnancy increases the risk of maternal
and perinatal morbidity and mortality, and is associated
with premature labour and low birth weight [2-4]. Know-
ing the prevalence of anaemia in pregnancy is a useful
measure of the health and nutritional status of pregnant
women. At the health facility level, it is important for
individual case management and planning of resources.
Prior studies have documented the risk factors for
anaemia in pregnancy to include malaria [5-7], Human* Correspondence: ononge2006@yahoo.com
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unless otherwise stated.Immunodeficiency virus (HIV) [7-10] and teenage preg-
nancies [11-13]. However, there is inconsistent evidence
of an association between high parity (5+) and anaemia
in pregnancy. While some studies show high parity in-
creases risk [14,15], others show no increased risk [16].
Effective interventions to prevent anaemia in pregnancy
include preconception and prenatal iron supplementa-
tion, and intermittent presumptive treatment of malaria
(IPT) [17].
According to the last two Uganda Demographic and
Health Surveys, there was a decline in the prevalence of
anaemia in pregnancy in Uganda from 41.2% to 30.5%
between 2001 and 2011 respectively [18]. Beyond the high
levels, we do not have recent information on the factors
contributing to anaemia in pregnancy. This study aims
to assess the haemoglobin levels and anaemia status of
pregnant women attending antenatal clinic in their 3rdl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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factors influence this status.
Methods
In the period 14th February 2013 to 30th November
2013, the study approached pregnant women attending
antenatal -care in six health centres in Mpigi district
and requested them to participate in a community trial
of self-administered misoprostol when delivery occurred
at home or when oxytocin or misoprostol were not avail-
able during facility delivery. Mpigi district headquarters is
33 kilometres from Kampala, the capital city of Uganda.
The majority of people in the district are of low socioeco-
nomic status, with peasant farming and fishing as the
main occupations. This paper is a cross-sectional descrip-
tion of prevalence of anaemia in pregnancy, and the base-
line factors that influenced the haemoglobin status of
study participants.
The study population were pregnant women at 28+
weeks of gestation, attending antenatal care, with no plans
to leave the area during pregnancy or in the immediate
postpartum. Women with a planned elective caesarean
section were excluded. The recruitment of study partici-
pants was as follows: when pregnant women had assem-
bled and had their routine antenatal health education,
they were briefed about the study objectives and design.
Eligible women were invited to participate, and if they
agreed, to give written informed consent. Study partici-
pants were then interviewed face-to-face by trained re-
search assistants. The pre-tested questionnaire was used
to collect maternal age, education and occupation, marital
status, religious affiliation, transport cost to the health
facility and delivery plans. The study also inquired about
parity, the gestation of the first antenatal visit, prophylac-
tic medications received in the course of pregnancy (anti-
helminthics, IPT & iron supplementation), and episodes
of malaria (self-reported fever or laboratory-tested) and
anti-malarial treatment. The women’s gestational age was
established using their last normal menstrual period
(LNMP) or ultrasound scan estimation. In a few cases
where we were unable to estimate gestational age by
LNMP or ultrasound scan, fundal height estimation
was used to approximate gestational age. Haemoglobin
levels were measured at the same time using a portable
HemoCueR Hb 301 system. The research assistants were
trained to estimate haemoglobin using the HemoCue.
Capillary blood was collected from participants using a
finger prick method under sterile conditions. The first
drop of blood was wiped away using alcohol sterile
wipes, and the next drop was placed into the Hemocue
curvette for immediate testing of haemoglobin.
Double data entry was done using EpiData 3.1 (EpiData
Association, Odense, Denmark). The data were analysed
using Stata version 12 (Stata Corp, College Station, TX,USA). Descriptive statistics were used to characterize the
study participants and their haemoglobin level status. To
adjust for the altitude of the study setting, 0.1 g/dl was
subtracted from measured haemoglobin in accordance
with WHO recommendations [19]. Anaemia was de-
fined as a haemoglobin level in pregnancy of less than
11.0 g/dl [20].
Means of haemoglobin and proportions of women
with anaemia across categories of each covariate were
performed using univariate and multivariate linear or
logistic regression models. Variables with P < 0.2 in the
univariate analyses were retained in the multivariate lo-
gistic regression model to determine which factors were
independently associated with haemoglobin status and
anaemia in third trimester of pregnancy. Maternal age,
parity, gestational age at enrolment, iron supplementa-
tion, IPT, malaria episodes in current pregnancy, and
HIV sero-status were included in the multivariate model
Permission to carry out the study was granted by the
School of Medicine Research and Ethics Committee at
Makerere University, Kampala, Uganda, and the Uganda
National Council for Science and Technology. The
study was registered with the Pan African Clinical Trials
Network (PACTR201303000459148).
Results
A total of 2545 eligible women were approached, 2466
(96.9%) of whom consented to participate. Data for
haemoglobin were obtained for 2436 women (98.8%).
Table 1 characterizes the study participants and the
mean haemoglobin levels of the women. The mean age
was 24.5 (±5.6) years (range: 14–48 years), 88% (2141/
2436) were married and average years of education
were 8 (±3.0). Approximately one quarter (641/2436) of
the participants were primigravida and mean parity was
3.1 (±2.1). The mean gestational age at the first prenatal
visit was 22.2 (±6.5) weeks. The average gestation at enrol-
ment in our study was 32.3 (±3.4) weeks. Approximately
one-third (34.1%) of women had not started iron supple-
ments before enrolling into the study. Women who had
taken the recommended two doses of de-worming tablets
and two doses of antimalarial prophylaxis were 31.4% and
38.2% respectively. One hundred and ninety (7.8%) of the
participants were HIV positive and 9 (0.4%) had undeter-
mined HIV sero-status. The women’s mean haemoglobin
level at enrolment was 11.5 (±1.38) g/dl and median was
11.6 g/dl (range: 6.9 - 15.9 g/dl). Seven hundred eighty five
(32.2%) had moderate anaemia (Hb 7.0-10.9 g/dl), and
0.3% had severe anaemia (Hb <7.0 g/dl).
In the univariate linear regression analysis (Table 1),
there was a significant difference in haemoglobin level
by various characteristics. Those less than 20 years and
those above 34 years had a lower mean haemoglobin
than those in the age range of between 20–34 years.
Table 1 Participants’ characteristics and the mean haemoglobin status of 2436 pregnant women
Characteristic Frequency Percent (%) Mean (sd) of Hb 95% CI P- value*
Overall haemoglobin 2436 100 11.5 (1.38) 11.6-11.7
Age in years
Below 20 474 19.5 11.3 (1.33) 11.2-11.4 0.006
20-24 937 38.5 11.5 (1.40) 11.4-11.6
25-29 680 27.9 11.6 (1.36) 11.5-11.7
30-34 176 7.2 11.5 (1.52) 11.3-11.8
≥35 169 6.9 11.5 (1.34) 11.3-11.7
Marital status
Single 295 12.1 11.4 (1.44) 11.2-11.5 0.055
Married 2141 87.9 11.5 (1.37) 11.5-11.6
Education level
No formal 77 3.2 11.8 (1.46) 11.5-12.1 0.437
Lower Primary (P1-4) 169 6.9 11.4 (1.38) 11.2-11.6
Upper Primary (P5-7) 967 39.7 11.5 (1.37) 11.4-11.6
Secondary (S1-S6) 1158 47.5 11.5 (1.40) 11.4-11.6
Tertiary 65 2.7 11.5 (1.27) 11.1-11.8
Parity
Nulliparous 641 26.3 11.4 (1.37) 11.3-11.5 0.083
1 582 24.0 11.5 (1.40) 11.4-11.6
2 414 17.0 11.6 (1.33) 11.5-11.7
3 286 11.7 11.6 (1.39) 11.5-11.8
4 228 9.4 11.5 (1.36) 11.5-11.6
Para 5+ 285 11.7 11.6 (1.43) 11.4-11.7
Timing of 1st visit
First trimester 251 10.3 11.3 (1.35) 11.1-11.5 0.034
Second trimester 1505 61.8 11.5 (1.38) 11.5-11.6
Third trimester 680 27.9 11.5 (1.40) 11.4-11.6
Iron supplements (number of tablets)
None 830 34.1 11.3 (1.38) 11.2-11.4 <0.001
1-30 1157 47.4 11.6 (1.37) 11.5-11.7
31-60 302 12.5 11.6 (1.34) 11.5-11.9
61+ 147 6.0 11.8 (1.44) 11.5-11.9
Doses of anti-helminthics taken
Zero 511 21.0 11.4 (1.39) 11.3-11.6 0.15
One 1162 47.7 11.5 (1.37) 11.4-11.6
Two 763 31.3 11.6 (1.38) 11.5-11.7
Doses of antimalarial prophylaxis (IPT)
Zero 433 17.8 11.4 (1.44) 11.3-11.6 0.004
One 1074 44.1 11.4 (1.36) 11.4-11.5
Two 929 38.1 11.6 (1.37) 11.5-11.7
Episodes of malaria
None 1501 61.6 11.6 (1.35) 11.5-11.7 0.024
One 568 23.3 11.4 (1.44) 11.3-11.7
Two 239 9.8 11.3 (1.40) 11.1-11.6
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Table 1 Participants’ characteristics and the mean haemoglobin status of 2436 pregnant women (Continued)
Three 91 3.7 11.6 (1.36) 11.3-12.0
Four + 37 1.5 11.3 (1.59) 10.9-11.9
HIV sero-status
Negative 2237 91.8 11.6 (1.36) 11.5-11.6 <0.001
Positive on ARVs 167 6.9 11.0 (1.52) 10.8-11.2
Positive ARV naive 23 0.9 11.0 (1.38) 10.4-11.5
Unknown 9 0.4 11.1 (1.28) 10.2-12.0
Hb: Haemoglobin, IPT: Intermittent prophylactic treatment, ARVs: antiretroviral drugs. *p-values are from the F-test at univariate analysis.
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first trimester had a significantly lower mean haemoglo-
bin level than the late starters. Women who had been
on iron supplements had a higher mean haemoglobin
than those that had not started taking any iron tablets.
The pregnant women who had received two doses of
anti-malarials for intermittent prophylaxis for malaria
(IPT) had higher mean haemoglobin than those who
had none or had taken only one dose. Women who had
not had malaria had higher mean level than those who
had suffered from malaria. Women who had received
two doses of antihelminthics had slightly a higher mean
haemoglobin than those who had taken one or zero
antihelminthics. HIV positive women had lower mean
haemoglobin than HIV negative women did.
In multivariate linear regression analysis (Table 2), ges-
tational age at enrolment and iron supplementation were
positively and independently associated with haemoglo-
bin level while malaria and HIV infections were nega-
tively associated with haemoglobin level.
Anaemia in third trimester of pregnancy
The study showed that in the third trimester, the preva-
lence of anaemia (Hb < 11.0 g/dl) was 32.5% (95% CI:
30.6%, 34.3%). The factors that had strong association with
anaemia in pregnancy, as shown in Table 3, were malaria,
HIV infection and iron supplementation. The effect of
malaria episodes and HIV infection on anaemia increased
after adjusting for potential confounders. Women who
were on iron supplementation were less likely to have
anaemia. Primigravida showed a weak positive association
with anaemia but this was reduced in the adjusted model.
Women who had fewer than the two doses of IPT showed
a positive association with anaemia, but this was reduced
in the adjusted model.
Discussion
Among pregnant women in third trimester receiving
antenatal clinic at Mpigi health facilities, the mean
haemoglobin was 11.5 (±1.38) g/dl and the prevalence of
anaemia (Hb < 11.0 g/dl) was 32.5% (95% CI 30.6-34.3).
In the multivariable analysis, haemoglobin status of
women was positively associated with early gestationalage at enrolment or iron supplementation, and nega-
tively associated with malaria and HIV infection. The
odds of being anaemic in pregnancy were significantly
associated with malaria (OR: 1.32, 95% CI: 1.11, 1.58),
HIV (OR: 2.13, 95% CI: 1.56, 2.90) and lack of iron sup-
plementation (OR: 1.66, 95% CI: 1.36, 2.03) after adjust-
ing for measured confounders. A weak association found
between parity and antimalarial prophylaxis (IPT) and
anaemia disappeared after adjusting for confounders.
Not all pregnant women in Mpigi district attend ante-
natal clinics at the public health facilities, however, the
Uganda Demographic Health Survey 2011 suggests that
94.9% of Ugandan women attend ANC at least once in
pregnancy [21]. Moreover, from the district monthly
reports, the number of pregnant women attending ante-
natal clinic at the government health facilities increased
after free obstetric ultrasound scans were introduced for
all the women, supported by STRIDES for family health,
a USAID funded project. This attracts pregnant women
and partners who are enthusiastic to know the status of
the fetus in utero. Antenatal attendance is also encour-
aged by the TBAs surveyed prior to the trial, who stated
they were less willing to attend to pregnant women who
had not attended antenatal care at the health facility. Ex-
cluding the 79 pregnant women (planned for caesarean
section birth, staying in island and moving out of Mpigi)
is likely to have had a negligible effect on the overall
prevalence of anaemia. For these reasons, and because of
the high response rate, we feel our results are likely to
be representative of the population of pregnant women
in this area.
The methods for measuring Hb and the cut-offs for
anaemia were as recommended by WHO [20]. Our as-
sessment of malaria was based on a history of fever and
of having received treatment of malaria from qualified
medical personnel. While this may be better than studies
that rely on women’s self-reports, we might still have
overestimated the prevalence of malaria in pregnant
women because there are many causes of fever in this
country
The mean haemoglobin level of the pregnant women
was higher than that reported by studies in Tanzania
and Ghana [7,22]. Both Tanzanian and Ghana studies
Table 2 Effects of different variables on haemoglobin status of pregnant women expressed as regression coefficients
(β) with 95% CI
Crude analysis Adjusted analysis
Characteristic β (95% CI) P-value β (95% CI) P- value*
Age in years
Below 20 −0.21 (−0.36, −0.06) 0.006 −0.19 (−0.36, −0.02) 0.07
20-24 Ref
25-29 0.11 (−0.03, 0.24) 0.10 (−0.06, 0.25)
30-34 0.02 (−0.20, 0.24) −0.03 (−0.28, 0.23)
≥35 −0.03 (−.26, 0.19) −0.05 (−0.34, 0.23)
Parity
Nulliparous −0.20 (−0.37, −0.03) 0.08 −0.14 (−0.33, 0.06) 0.38
1 −0.12 (−0.30, 0.05) −0.12 (−0.30, 0.05)
2 Ref Ref
3 0.05 (−0.16, 0.26) 0.05 (−0.16, 0.26)
4 −0.10 (−0.33, 0.12) −0.12 (−0.35, 0.12)
Para 5+ −0.01 (−0.22, 0.20) 0.03 (−0.22, 0.29)
Timing of 1st antenatal visit
1st trimester Ref 0.03 Ref 0.05
2nd trimester 0.24 (0.06, 0.43) 0.21 (0.03, 0.40)
3rd trimester 0.20 (0.00, 0.40) 0.26 (0.04, 0.48)
Gestational age at enrolment 0.05 (0.03, 0.06) <0.001 0.03 (0.01, 0.05) <0.001
Iron supplements (number of tablets)
None Ref <0.001 <0.001
1-30 0.27 (0.15, 0.39) 0.32 (0.19, 0.45)
31-60 0.40 (0.22, 0.58) 0.37 (0.17, 0.58)
61+ 0.47 (0.23, 0.71) 0.53 (0.27, 0.80)
Doses of antihelminthics taken
Zero −0.14 (−0.30, 0.01) 0.15 0.12 (−0.11, 0.35) 0.54
One −0.10 (−0.22, 0.03) 0.09 (−0.10, 0.28)
Two Ref
Doses of antimalarial prophylaxis (IPT)
Zero −0.21 (−0.37, −0.05) 0.004 0.03 (−0.20, 0.25) 0.20
One −0.18 (−0.30, −0.06) −0.12 (−0.30, 0.06)
Two Ref
Episodes of malaria
None Ref 0.02 0.02
One −0.13 (−0.26, 0.003) −0.14 (−0.27, −0.01)
Two −0.29 (−0.48, −0.10) −0.29 (−0.47, −0.10)
Three −0.01 (−0.30, 0.28) 0.01 (−0.29, 0.29)
Four + −0.19 (−0.64, 0.26) −0.16 (−0.60, 0.29)
HIV Sero-status
Negative Ref <0.001 <0.001
Positive −0.54 (−0.74, −0.33) −0.63 (−0.85, −0.42)
HIV: Human Immunodeficiency Virus; ARVs: Antiretroviral treatment.
*p-values are from the F-test after adjusting for variables that had a univariate p-value <0.2 (age, parity timing of first ANC visit, gestational age at enrolment, iron
supplementation, antihelminthics, IPT malaria & HIV infection).
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Table 3 Factors associated with of anaemia in third trimester of pregnancy in Mpigi, Uganda
Crude analysis Adjusted analysis*
Characteristic Frequency Women with
Hb < 11.0 g/dl n (%)
OR (95% CI) of
Hb < 11.0 g/dl
P- value (trend) OR (95% CI) P value (trend)
Overall anaemia 2436 791 (32.5)
Age in years
Below 20 474 186 (39.2) 1.38 (1.10-1.74) 0.008 (0.016) 1.21 (0.93-1.58) 0.26(0.18)
20-24 937 298 (31.8) 1 1
25-29 680 199 (29.3) 0.89 (0.72-1.10) 0.87 (0.68-1.12)
30-34 176 52 (29.6) 0.90 (0.63-1.28) 0.86 (0.57-1.31)
≥35 169 56 (31.1) 1.06 (0.75-1.51) 0.99 (0.63-1.57)
Marital status
Single 295 110 (37.3) 1.27 (0.98-1.64) 0.06 0.93 (0.70-1.21) 0.58
Married 2141 681 (31.8) 1 1
Education level
No formal 77 24 (31.2) 1 0.98 (0.94)
Lower primary (P1-P4) 169 56 (33.1) 1.09 (0.61-1.95)
Upper primary (P5-P7) 967 314 (32.5) 1.06 (0.64-1.75)
Secondary(S1-S6) 1158 378 (32.6) 1.07 (0.65-1.76)
Tertiary 65 19 (29.2) 0.91 (0.44-1.87)
Parity
Nulliparous 641 244 (38.1) 1.57 (1.21-2.06) 0.004 (0.024) 1.48 (1.08-2.04) 0.08 (0.13)
1 582 186 (32.0) 1.21 (0.92-1.59) 1.22 (0.91-1.63)
2 414 116 (28.0) 1 1
3 286 78 (27.3) 0.96 (0.69-1.35) 0.98 (0.69-1.39)
4 228 79 (34.7) 1.36 (0.96-1.93) 1.42 (0.97-2.07)
Para 5+ 285 88 (30.1) 1.14 (0.82-1.60) 1.14 (0.76-1.71)
Timing of 1st visit
First trimester 251 92 (36.7) 1 0.10 (0.9) 1 0.22 (0.15)
Second trimester 1504 466 (31.0) 0.78 (0.59-1.02) 0.79 (0.59-1.05)
Third trimester 672 231 (34.4) 0.90 (0.67-1.22) 0.75 (0.54-1.05)
Episodes of malaria
Zero 1501 454 (30.3) 1 0.003 1 0.002
One or more 935 337 (36.0)) 1.30 (1.09-1.54) 1.32 (1.11-1.58)
HIV Sero-status
Negative 2246 703 (31.3) 1 <0.001 1 <0.001
Positive 190 88 (44.0) 1.89 (1.40-2.55) 2.13 (1.56-2.90)
Iron sulphate taken
None 830 322 (38.8) 1.54 (1.29-1.83) <0.001 1.66 (1.36-2.03) <0.001
Yes 1606 469 (29.2) 1 1
Doses of IPT
Two 929 271 (29.2) 1 0.06 1 0.15
One or none 1507 520 (34.5) 1.28 (1.07-1.53) 1.15 (0.95-1.40)
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Table 3 Factors associated with of anaemia in third trimester of pregnancy in Mpigi, Uganda (Continued)
Doses of anti-helminthics taken
One + 1925 617 (32.1) 1 0.39
Zero 511 174 (34.1) 1.09 (0.89-1.35)
Hb: Haemoglobin; OR: Odds ratios; IPT: Intermittent presumptive treatment of malaria.
P-values are from the likelihood ratio test, *adjusted for age, parity, marital status, iron tablets intake, IPT, malaria, timing of first antenatal visit and HIV-sero-status.
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pregnancy when haemo-dilution occurs [23]. Our study
recruited women in the third trimester when haemoglo-
bin levels in normal women tend to rise slightly. Our
study also showed that the later the gestational age at
enrolment, the higher the haemoglobin level. Similarly
higher haemoglobin levels were observed with iron
supplementation. However, women who had malaria or
HIV infections had a decrease in their haemoglobin
level, as might be expected [8,24,25].
The prevalence of anaemia (Hb < 11.0 g/dl) in this
population of pregnant women was high (32.5%) and was
in the range of that reported in the Uganda Demographic
and Health Survey (UDHS 2011 which was 30.6%) [21].
However, this was lower than the level of 39.7% obtained
during an earlier 2003–2005 study in Uganda [8]. The dif-
ference could be due to the cut off for anaemia (Hb < 11.2,
adjusted for altitude) used in the Muhangi study was
higher than ours despite being at a similar altitude or
because of improvements in socioeconomic status of the
population over time. Socioeconomic status is a known
determinant of anaemia [26,27].
The study found an association between lack of iron
supplementation and anaemia in pregnancy. Women who
were not taking iron supplements had approximately a
60% higher odds of anaemia. This was different from a
study in Cleveland, USA that did not find any effect of
iron supplementation on reduction of anaemia in preg-
nancy [28]. The possible reason why the Cleveland study
was not able to observe an association between iron
supplementation and anaemia is that they enrolled only
participants who had adequate iron stores or had no
anaemia. The authors also noted in the paper a low power
of the study due to loss-to-follow-up. This could have
affected the effect estimate of iron supplementation on
anaemia. However our finding are supported by a number
of publications that document reduction in the level of an-
aemia in the ranges of 58%-83% when iron supplementa-
tion is given in randomized controlled trials [2,29-31].
Our study also showed that malaria in pregnancy was
strongly associated with anaemia. The relationship be-
tween malaria and anaemia in pregnancy has been docu-
mented in several studies [7,8,32]. These findings call for
more effort to be put into malaria preventive strategies
in the community in order for us to reduce the effects of
morbidity and mortality related to anaemia.Results in our study showed that pregnant women
with HIV infection were twice more likely to have
anaemia than HIV negative. A number of studies have
documented HIV as a cause of anaemia in pregnancy
[7,9,24,25,33-35]. HIV infection is associated with lower
levels of serum folate and serum ferritin [10]. It is also
suggested that HIV infection causes anaemia through
changes in cytokine production, altered erythropoietin
response to bone marrow and use of antiretroviral drugs,
especially Zidovudine [24]
Conclusion
Our study showed a decreasing prevalence of anaemia
with increasing iron supplements used by the pregnant
woman. This demonstrated that even in real life setting,
iron supplementations in pregnant women appears to
reduce the risk of anaemia. Nevertheless, 34.1% of women
in our study had taken no iron supplementation, and
coverage of IPT was also low (29.2%). We need to under-
take additional measures to enable more pregnant women
to start iron supplementation from the first trimester. This
is possible by creating awareness through the village
health teams (VHT) who can also be a channel for iron
distribution.
Malaria and HIV in pregnancy were significantly associ-
ated with anaemia pregnancy. There is a need to reinforce
malaria and HIV prevention strategies in the country, for
example sleeping under insecticide treated nets for and
behavioural change. There is a need to reactivate the
1990’s vigour in prevention of HIV/AIDs in the communi-
ties, where Government openly acknowledged HIV/AIDS
as a public health problem and supported public media
campaign that ensued to mobilise communities to the
fight against HIV/AIDS.
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